Willingness-to-pay to access Ingenol Mebutate Gel for Actinic Keratosis Treatment in the U.S. Setting
暂无分享,去创建一个
M. Willis | U. Persson | J. Norlin | S. Erntoft | S. Persson
[1] A. Carr,et al. Non-adherence to topical treatments for actinic keratosis , 2013, Patient preference and adherence.
[2] A. Pickert. Treatment of actinic keratoses. , 2012, Cutis.
[3] Neil Swanson,et al. Ingenol mebutate gel for actinic keratosis. , 2012, The New England journal of medicine.
[4] R. Wanitphakdeedecha,et al. Measuring melasma patients' quality of life using willingness to pay and time trade-off methods in thai population , 2011, BMC Dermatology.
[5] S. Feldman,et al. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. , 2011, Cutis.
[6] G. Goldenberg,et al. What's new in the treatment of actinic keratoses? , 2011, Cutis.
[7] M. Ulrich,et al. Emerging drugs for actinic keratosis , 2010, Expert opinion on emerging drugs.
[8] N. Swanson,et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. , 2010, Journal of the American Academy of Dermatology.
[9] C. Garbe,et al. Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.
[10] M. Weinstock,et al. Quality of life in the actinic neoplasia syndrome: The VA Topical Tretinoin Chemoprevention (VATTC) Trial. , 2009, Journal of the American Academy of Dermatology.
[11] M. Radtke,et al. Willingness‐to‐pay and quality of life in patients with vitiligo , 2009, The British journal of dermatology.
[12] E. Tschen,et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. , 2009, Journal of the American Academy of Dermatology.
[13] A. Qureshi,et al. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: a pilot study. , 2008, Journal of the American Academy of Dermatology.
[14] Suephy C. Chen,et al. Patient preference quality of life measures in dermatology , 2007, Dermatologic therapy.
[15] Felix Schläpfer. Survey protocol and income effects in the contingent valuation of public goods: A meta-analysis , 2006 .
[16] Thomas Laitila,et al. Economic Valuation with Stated Preference Techniques: A Manual , 2004 .
[17] M. Lebwohl,et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. , 2004, Journal of the American Academy of Dermatology.
[18] H. Korting,et al. Actinic Keratosis: The Key Event in the Evolution from Photoaged Skin to Squamous Cell Carcinoma , 2004, Skin Pharmacology and Physiology.
[19] M. Lebwohl,et al. Actinic keratosis: epidemiology and progression to squamous cell carcinoma , 2003, The British journal of dermatology.
[20] S. Feldman,et al. The Importance of Skin Disease as Assessed by “Willingness-To-Pay” , 2003, Journal of cutaneous medicine and surgery.
[21] W. Stolz,et al. Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients? , 2003, The British journal of dermatology.
[22] W. Stolz,et al. Willingness to pay and time trade-off: useful utility indicators for the assessment of quality of life and patient satisfaction in patients with port wine stains. , 2002, The British journal of dermatology.
[23] J. Bothwell,et al. Prevalence of solar damage and actinic keratosis in a Merseyside population , 2000, The British journal of dermatology.
[24] M. Johannesson,et al. Quality of life, health‐state utilities and willingness to pay in patients with psoriasis and atopic eczema , 1999, The British journal of dermatology.
[25] C. Frost,et al. Epidemiology of solar keratoses , 1994, The British journal of dermatology.
[26] J E Hewett,et al. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. , 1991, Archives of dermatology.
[27] A. Finlay,et al. How much disability is caused by acne? , 1989, Clinical and experimental dermatology.
[28] E. Benton,et al. HUMAN PAPILLOMA VIRUS INFECTION AND SKIN CANCER IN RENAL ALLOGRAFT RECIPIENTS , 1989, The Lancet.
[29] G. Rennie,et al. MALIGNANT TRANSFORMATION OF SOLAR KERATOSES TO SQUAMOUS CELL CARCINOMA , 1988, The Lancet.
[30] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .
[31] R. Marks,et al. Spontaneous remission of solar keratoses: the case for conservative management , 1986, The British journal of dermatology.
[32] S. Feldman,et al. Pharmacoeconomic Considerations in Treating Actinic Keratosis , 2012, PharmacoEconomics.
[33] J. Q. Rosso,et al. Actinic Keratoses: Natural History and Risk of Malignant Transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial , 2010 .
[34] J. Jorizzo. Current and Novel Treatment Options for Actinic Keratosis , 2004, Journal of cutaneous medicine and surgery.
[35] S. Salasche,et al. Epidemiology of actinic keratoses and squamous cell carcinoma. , 2000, Journal of the American Academy of Dermatology.
[36] M. Turner,et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. , 1995, Journal of the American Academy of Dermatology.
[37] M. Turner,et al. Guidelines of care for actinic keratoses , 1995 .